Nanoparticles and Liposomal products have significantly contributed for managing various disorders and diseases. Drug delivery system is important and assisting in developing various therapeutic regimen. The present write-up discussed the role of novel drug delivery system, particularly applications of nanoparticles and liposomal products and regulatory requirement for these products. The article emphasises that there are enormous research opportunities and global collaboration is essential for promoting research and drug approval.
DeamerDW. From “banghasomes” to liposomes: a memoir of Alec Bangham, 1921–2010. Faseb J2010; 24(5): 1308–1310.
2.
JohnstonMJSempleSCKlimukSK, et al.Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin. Biochim Biophys Acta2007; 1768(5): 1121–1127.
3.
MuLSprandoRL. Application of nanotechnology in cosmetics. Pharm Res2010; 27: 1746–1749.
4.
LaouiniAJaafar-MaalejCLimayem-BlouzaI, et al.Preparation, characterization and applications of liposomes: state of the art. J Coll Sci Biotechnol2012; 1(2): 147–168.
5.
EdwardsKABaeumnerAJ. Liposomes in analyses. Talanta2006; 68(5): 1421–1431.
ProvderT. Challenges in particle size distribution measurement past, present and for the 21st century. Prog Org Coating1997; 32(1-4): 143–153.
8.
SchlieperPMeddaPKKaufmannR. Drug-induced zeta potential changes in liposomes studied by laser doppler spectroscopy. Biochim Biophys Acta1981; 644(2): 273–283.
9.
WangTDengYGengY, et al.Preparation of submicron unilamellar liposomes by freeze-drying double emulsions. Biochim Biophys Acta2006; 1758(2): 222–231.
10.
GilletALecomteFHubertP, et al.Skin penetration behaviour of liposomes as a function of their composition. Eur J Pharm Biopharm2011; 79(1): 43–53.
11.
ElsayedMMAbdallahOYNaggarVF, et al.Deformable liposomes and ethosomes: mechanism of enhanced skin delivery. Int J Pharm2006; 322(1-2): 60–66.
12.
NagayasuAUchiyamaKKiwadaH. The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Adv Drug Deliv Rev1999; 40(1-2): 75–87.
13.
MalamYLoizidouMSeifalianAM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci2009; 30(11): 592–599.
14.
MalikRPatilS. Nanotechnology: regulatory outlook on nanomaterials and nanomedicines in United States, Europe and India. Appl Clinical Res, Clinical Tri Regul Aff2020; 7(3): 225–236.
15.
HeneweerCGendySEPeñate-MedinaO. Liposomes and inorganic nanoparticles for drug delivery and cancer imaging. Ther Deliv2012; 3(5): 645–656.
16.
DupontB. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother2002; 49(suppl_1): 31–36.
